TNF blockers get child cancer warning

FDA is tacking new, stronger warnings on TNF-alpha blockers. The new label language highlights an increased risk of cancer in children and adolescents who take the blockbuster meds. These drugs

Documents detail Wyeth's ghostwriting practices

In another round of ethical questions for drugmakers and medical journals, newly unveiled court documents show that Wyeth paid ghostwriters to author some 26 articles supporting hormone replacement

Extremists accused in attacks on Novartis chief

In a frightening turn of events for Novartis chief Daniel Vasella, extremists have not only set fire to his vacation home in the Tyrol, but desecrated his mother's grave. Law enforcement in Austria

Eli Lilly offers buyouts to 4,000 reps

Is another wave of sales-rep cuts in the offing? Well, at least one Big Pharma is once again revamping its marketing ops: Eli Lilly is offering buyouts to 4,000 U.S. reps, in hopes of shedding

Toprol OK's a boon for Watson amid shortage

Watson Pharmaceuticals could reap big benefits from the approval of its version of the blood pressure med Toprol XL, because two rival generic drugs were suspended because of manufacturing problems.

Antiflu meds safe as preventive remedies

With Roche's Tamiflu among the linchpin pandemic-flu remedies, the drug is getting more scrutiny than ever before--some good, some not so much. On the good side of the ledger, researchers found that

AZ deals in Japan, Lilly trains in Russia

As if to underscore the growing importance of international drug markets, today's news was full of developments from around the globe, particularly Asia. Drug co-promotions, manufacturing standards,

Emerging market success doesn't come easy

No doubt, 2009 is the year of the emerging market. We all know that Big Pharma has been falling all over itself, moving into the developing world by leaps and bounds. You know the

U.S. antidepressant use almost doubles

We all know that antidepressant use has skyrocketed in the U.S. That drug class encompasses some of the biggest-selling meds in pharma. But a new study shows just how much the market has grown: The

Does Merck exit signal a shake-up?

In a surprise departure, Merck vaccines chief Margaret McGlynn (photo) has announced her retirement. Though McGlynn had been eclipsed by EVP Kenneth Frazier in recent years, she was once considered a

Avastin gets another FDA nod

Roche's Avastin got FDA approval for the most common type of kidney cancer, based on a study showing that patients on the drug in combination with intereron alpha lived nearly twice as long without

Januvia gets head-to-head rival in Onglyza

Watch out, Januvia. AstraZeneca and Bristol-Myers Squibb finally won FDA approval for their diabetes drug Onglyza, a DPP-4 inhibitor that will directly compete with Merck's fast-growing treatment.

Growth-happy Nycomed buys Sanofi drug rights

Nycomed isn't stopping at its bid for Solvay's pharma division. The Swiss company has snapped up rights to 20 branded generic drugs, aiming to beef up its business in central and eastern Europe. "The

Reform passes House with pros, cons for pharma

Want pharma's good news first? The House Energy and Commerce Committee attached a provision for 12 years of biologic drug exclusivity to broader healthcare reform legislation. That's despite calls

FDA bars Teva vet drugs on compliance issues

More manufacturing problems, more FDA action. This time it's Teva Pharmaceuticals in the stocks--but veterinary meds, not people drugs. The FDA announced late Friday that it had filed a consent

Lilly details $22M in doc payments

Eli Lilly has made good on its disclosure promise. The company released its new "faculty registry," a compendium of consulting payments to doctors for the first quarter of this year. Grand total: $22

Ranbaxy Labs awaits FDA re-inspection

Ranbaxy Laboratories said FDA may start inspection of its Dewas, India, plant "any time now," moving the Indian company closer to resuming exports to the world's largest pharmaceutical market from

PwC foresees drugmaker-diagnostics alliances

Experts have been promising us personalized medicine for years now. Now they're doing it again: The analysts at PricewaterhouseCoopers issued a report predicting that drugmakers and diagnostics firms

Japan's drugmakers post so-so results

Japan's drugmakers are suffering from the strong yen (among other things). Three of the biggies--Takeda, Daiichi Sankyo and Eisai--posted either declining sales or declining earnings, or both.

Swine flu could be FluMist's moment

Swine flu could be MedImmune's watershed moment. The company says it's gearing up to produce about five times as much H1N1 flu vaccine as it had expected, the New York Times reports. With